119 related articles for article (PubMed ID: 38251775)
21. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
22. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
23. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
24. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
25. Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy.
Xiao H; Xiao Y; Chen P; Quan H; Luo J; Huang G
Ann Surg Oncol; 2021 Apr; 28(4):2394-2404. PubMed ID: 32929601
[TBL] [Abstract][Full Text] [Related]
26. Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis.
Matsui R; Inaki N; Tsuji T
Clin Nutr; 2021 May; 40(5):2745-2753. PubMed ID: 33933740
[TBL] [Abstract][Full Text] [Related]
27. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Survival Between ypStage and pStage in Gastric Cancer.
Komori K; Yamada T; Ando S; Hashimoto I; Watanabe H; Maezawa Y; Fujikawa H; Sawazaki S; Numata M; Aoyama T; Yukawa N; Rino Y; Saito A; Ogata T; Oshima T
Anticancer Res; 2024 Jun; 44(6):2661-2670. PubMed ID: 38821586
[TBL] [Abstract][Full Text] [Related]
29. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].
Li S; Ma PF; Zhang JL; Cao YH; Liu CY; Zhang XJ; Li ZY; Xue YW; Zhao YZ
Zhonghua Yi Xue Za Zhi; 2021 Sep; 101(34):2703-2709. PubMed ID: 34510877
[No Abstract] [Full Text] [Related]
30. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China.
Yang Y; Ma Y; Xiang X; Xing P; Wu Y; Zhang L; Tian Y
Radiat Oncol; 2020 Oct; 15(1):237. PubMed ID: 33054848
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
32. Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Okubo K; Arigami T; Matsushita D; Tanaka T; Tsuruda Y; Noda M; Sasaki K; Mori S; Kurahara H; Ohtsuka T
Oncology; 2021; 99(6):380-388. PubMed ID: 33677434
[TBL] [Abstract][Full Text] [Related]
33. Prognosis After Laparoscopic Gastrectomy in Patients with Pathological Stage II or III Gastric Cancer Who Were Preoperatively Diagnosed with Clinical Stage I: Propensity Score Matching Analysis of a Multicenter Dataset.
Ito Y; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Ann Surg Oncol; 2020 Jan; 27(1):268-275. PubMed ID: 31493125
[TBL] [Abstract][Full Text] [Related]
34. Postoperative complications and prognosis after radical gastrectomy for gastric cancer: a systematic review and meta-analysis of observational studies.
Wang S; Xu L; Wang Q; Li J; Bai B; Li Z; Wu X; Yu P; Li X; Yin J
World J Surg Oncol; 2019 Mar; 17(1):52. PubMed ID: 30885211
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].
Li B; Sun L; Wang X; Deng J; Ding X; Wang X; Ke B; Zhang L; Zhang R; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):207-212. PubMed ID: 28226357
[TBL] [Abstract][Full Text] [Related]
36. Indications for Adjuvant Chemotherapy in Stage II Gastric Cancer After D2 Gastrectomy-A Chinese Multicenter Study.
Deng ZJ; Lu J; Nie RC; Fang JM; Chen XJ; Liu JJ; Li XZ; Chen YB; Huang CM; Lian L; Peng JS; Chen S
Ann Surg Oncol; 2022 Dec; 29(13):8214-8224. PubMed ID: 35798893
[TBL] [Abstract][Full Text] [Related]
37. Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi-institutional dataset.
Nakagawa N; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Cancer Med; 2018 Dec; 7(12):6020-6029. PubMed ID: 30411544
[TBL] [Abstract][Full Text] [Related]
38. Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
[TBL] [Abstract][Full Text] [Related]
39. Solitary living worsens the continuation of adjuvant chemotherapy for gastric cancer.
Nagasawa S; Sato T; Morita J; Kondo H; Tsuchiya N; Sato S; Takeda K; Aoyama T; Yukawa N; Rino Y; Kunisaki C
Eur J Surg Oncol; 2023 Feb; 49(2):368-375. PubMed ID: 36115784
[TBL] [Abstract][Full Text] [Related]
40. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
